CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Access Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Access Bio Inc
65 CLYDE ROAD, SUITE A
Phone: (732) 873-4040p:732 873-4040 SOMERSET, NJ  08873  United States Ticker: 950130950130
Business Summary
Access Bio, Inc. focuses on preventing and diagnosing infectious diseases early through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. The Company also launched diagnostic products, including tests for Coronavirus Disease 2019 (COVID-19), Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, dengue fever, influenza, and strep. The Company has commercialized products to combat malaria and other diseases. The Company’s product lineup includes COVID-19 Detection Kits -These kits assess the current or past presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Rapid Diagnostic Tests (RDTs) - RDTs are used for preliminary diagnosis or emergency medical screening in facilities with limited resources; Analyzers - Designed to measure various chemicals and characteristics in biological samples; and Molecular Diagnostics - These are used to analyze biological markers in the genome and proteome.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Yeong HoChoi 60
Assistant Managing Director Gyeong YeonHwang
Internal Auditor Jae YeonLee 59
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 63 (As of 9/30/2015)
Outstanding Shares: 35,173,834 (As of 9/30/2024)
Shareholders: 43,079
Stock Exchange: KDQ
Federal Tax Id: 460505083
Fax Number: (732) 873-4043


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025